Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction.
暂无分享,去创建一个
O. Hess | M. Togni | R. Cocchia | P. Wenaweser | S. Cook | S. Windecker | B. Meier | M. Billinger
[1] O. Hess,et al. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. , 1986, Circulation.
[2] O. Hess,et al. Coronary stenosis vasomotion during dynamic exercise before and after PTCA. , 1989, European heart journal.
[3] O. Hess,et al. Coronary vasomotor tone during static and dynamic exercise. , 1989, European heart journal.
[4] E. Nabel,et al. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. , 1989, The Journal of clinical investigation.
[5] J. Badimón,et al. Rapamycin inhibits vascular smooth muscle cell migration. , 1996, The Journal of clinical investigation.
[6] J. Roelandt,et al. Images in Cardiovascular Medicine , 2000 .
[7] R. Virmani,et al. Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.
[8] P. Tsao,et al. Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.
[9] Ranz,et al. DECREASED RATE OF CORONARY RESTENOSIS AFTER LOWERING OF PLASMA HOMOCYSTEINE LEVELS , 2001 .
[11] P. Serruys,et al. Angiographic Findings of the Multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): Sirolimus-Eluting Stents Inhibit Restenosis Irrespective of the Vessel Size , 2002, Circulation.
[12] P. Serruys,et al. Intravascular Ultrasound Findings in the Multicenter, Randomized, Double-Blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) Trial , 2002, Circulation.
[13] G. Koehl,et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.
[14] F. Eberli,et al. Exercise-Induced Coronary Artery Vasodilation Is Not Impaired by Stent Placement , 2002, Circulation.
[15] P. Serruys,et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.
[16] Antonio Colombo,et al. Mechanism of Late In-Stent Restenosis After Implantation of a Paclitaxel Derivate–Eluting Polymer Stent System in Humans , 2002, Circulation.
[17] P. Serruys,et al. Two-Year Angiographic and Intravascular Ultrasound Follow-Up After Implantation of Sirolimus-Eluting Stents in Human Coronary Arteries , 2003, Circulation.
[18] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[19] Patrick W Serruys,et al. Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the “Real World”: The R apamycin-E luting S tent E valuated A t R otterdam C ardiology H ospital (RESEARCH) Registry , 2004, Circulation.
[20] J. Moses,et al. Sirolimus-eluting stents vs. standard stents in patients with stenosis in a native coronary artery , 2004 .
[21] R. Virmani,et al. Images in cardiovascular medicine. Vascular healing 4 years after the implantation of sirolimus-eluting stent in humans: a histopathological examination. , 2004, Circulation.
[22] David J Cohen,et al. Stent Thrombosis After Successful Sirolimus-Eluting Stent Implantation , 2004, Circulation.
[23] Patrick W Serruys,et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.
[24] Giuseppe Musumeci,et al. Localized Hypersensitivity and Late Coronary Thrombosis Secondary to a Sirolimus-Eluting Stent: Should We Be Cautious? , 2004, Circulation.
[25] R. Virmani,et al. Preclinical restenosis models and drug-eluting stents: still important, still much to learn. , 2004, Journal of the American College of Cardiology.
[26] O. Hess,et al. Deleterious Effect of Coronary Brachytherapy on Vasomotor Response to Exercise , 2004, Circulation.
[27] Charles L. Brown,et al. Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis , 2004, Circulation.
[28] Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2005 .